A5011140176- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiovascular and exercise physiology
- Blood Pressure and Hypertension Studies
- Hemodynamic Monitoring and Therapy
- Congenital Heart Disease Studies
- Heart Rate Variability and Autonomic Control
- Cardiac pacing and defibrillation studies
- Pulmonary Hypertension Research and Treatments
- Non-Invasive Vital Sign Monitoring
- Chronic Kidney Disease and Diabetes
- Pediatric Urology and Nephrology Studies
- Kidney Stones and Urolithiasis Treatments
- Advanced Neuroimaging Techniques and Applications
- Attention Deficit Hyperactivity Disorder
- Erythropoietin and Anemia Treatment
- Cardiovascular Issues in Pregnancy
- Heart rate and cardiovascular health
- Advanced MRI Techniques and Applications
- Eicosanoids and Hypertension Pharmacology
- Cardiac Health and Mental Health
- Cardiac Structural Anomalies and Repair
- Acute Kidney Injury Research
- Functional Brain Connectivity Studies
- Urinary Tract Infections Management
Abbott (United States)
2020-2023
Burlington College
2023
Danaher (United States)
2020-2022
Scripps Clinic
2021
Abbott Fund
2021
AdventHealth Orlando
2020
Vanderbilt University Medical Center
2020
MRC Cognition and Brain Sciences Unit
2005
Washington University Medical Center
1998
George Washington University
1998
Background: Ambulatory hemodynamic monitoring with an implantable pulmonary artery (PA) sensor is approved for patients New York Heart Association Class III heart failure (HF) and a prior HF hospitalization (HFH) within 12 months. The objective of this study was to assess the efficacy safety PA pressure-guided therapy in routine clinical practice special focus on subgroups defined by sex, race, ejection fraction. Methods: This multi-center, prospective, open-label, observational, single-arm...
The CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF) investigated safety and efficacy of pulmonary artery pressure (PAP)-guided remote patient management (RPM) in New York Association (NYHA) class III outpatients with at least one heart failure hospitalization (HFH) during the previous 12 months. This pre-specified subgroup analysis whether RPM effects depended on presence subtype hypertension (PH).In 106/234 MEMS-HF participants, Swan-Ganz catheter tracings obtained sensor...
<h2>Abstract</h2><h3>Background</h3> Therapy guided by pulmonary artery (PA) pressure monitoring reduces PA pressures and heart failure hospitalizations (HFH) during the first year, but durability of efficacy safety through 2 years is not known. <h3>Methods Results</h3> The CardioMEMS Post-Approval Study investigated whether benefit were generalized sustained. Enrollment at 104 centers in United States included 1200 patients with NYHA Class III symptoms on recommended HF therapies prior HFH....
Background: Hemodynamic-guided heart failure management is a superior strategy to prevent decompensation leading hospitalization compared with traditional clinical methods. It remains unstudied if hemodynamic-guided care effective across severities of comorbid renal insufficiency or this impacts function over time. Methods: In the CardioMEMS US PAS (Post-Approval Study), hospitalizations were from 1 year before and after pulmonary artery sensor implantation in 1200 patients New York Heart...
Abstract Aims Chronic heart failure reduces quality and quantity of life is expensive for healthcare systems. Medical treatment relies on guideline‐directed therapy, but clinical follow‐up remote management highly variable poorly effective. New strategies are needed to maintain stability avoid hospitalizations acute decompensation. Methods results The CardioMEMS Post‐Market Study a prospective, international, single‐arm, multicentre, open‐label study (NCT02954341) designed examine the...
Background: Response to pharmacological and device-based therapy for heart failure (HF) may vary by sex. We examined sex differences in response ambulatory hemodynamic monitoring clinical practice using the CardioMEMS PAS (Post-Approval Study). Methods: The was a prospective, single-arm, multicenter, open-label study of 1200 adults with New York Heart Association class III HF at least 1 hospitalization (HFH) within 12 months who underwent pulmonary artery pressure sensor implantation between...
Control of pulmonary pressures monitored remotely reduced heart failure hospitalizations mainly by lowering filling through the use loop diuretics. Sacubitril/valsartan improves outcomes and increases kidney sensitivity for We explored whether sacubitril/valsartan is associated with less utilization diuretics in patients guided haemodynamic monitoring CardioMEMS European Monitoring Study Heart Failure (MEMS-HF).The MEMS-HF population (n = 239) was separated 68) or no it 164). Utilization...
We investigate the influence of physiological measures like heart beat and respiration on functional connectivity networks from fMRI. Cardiac respiratory effects were measured simultaneously during high rate MRI data acquisition determined in a driven manner using graph theory. One our findings is that removing leads to disappearance considerable part appearance small, but consistent networks. found further signal variance loss due effect removal does not coincide with correlation loss,...
898 Age predicted maximal heart rate (220-age) is used as a guide during clinical exercise testing and an integral component of submaximal fitness testing. However, it well known that individuals with mental retardation(MR), especially those Down syndrome (DS), have low rates(MHR). Thus, we evaluated the ability to predict MHR in MR DS comparison persons without MR. Subjects completed test on treadmill metabolic HR measurements. Stepwise multiple regression was develop prediction equations...
1882 The common formula for age predicted maximal heart rate (MHR) (220-age) is based on several studies, derived primarily from clinical exercise tests(CET). We evaluated the ability to predict MHR in two populations (age= 13-79 years), one that received treadmill tests with objective metabolic criteria effort (OMT) (n=548) and without measurements (CET) (n=3075). also if BMI, activity level gender contributed prediction of MHR. Stepwise multiple regression was used develop equations Using...
Introduction: Pulmonary artery pressure (PAP)-guided treatment reduces heart failure hospitalizations (HFH) in randomized and “real world” studies. Underlying CKD HF patients portends poorer outcomes. This analysis was performed to determine if benefit of PAP-guided therapy persists with increasing severity. Methods: retrospective cohort study conducted NYHA Class III recipients the PAP sensor enrolled CardioMEMS Post Approval Study. Patients were subdivided into quartiles glomerular...
Introduction: Effective management of ambulatory heart failure (HF) requires active patient (pt) participation. In telemonitoring weights and symptoms, pt adherence to transmission is often halved within 6 months (M). Although pulmonary pressure-guided decreases hospitalizations improves quality life, the time course perception illness sense security in relation monitoring frequency not known. Hypothesis: Pts will perceive decreased impact their HF during management, which may contribute...